For patients with G8 scores of 12 or lower, the overall survival rate after 2 years was 56.1%, and 28% after 5 years. In contrast, the respective 2- and 5-year overall survival rates for patients with G8 scores of 13 or higher were 94.1% and 68.4% (P = .0014).
In univariate analysis, factors significantly associated with survival included T-stage (P = .034), pathology (P = .004), and G8 score (P = .001). G8 score was also significantly associated with overall survival in multivariate analysis (P = .006).
Adverse events included rib fractures in nine patients, grade 2 pneumonitis in four and grade 3 pneumonitis in two patients. There were no cases of hemoptysis. Neither G8 score nor age were related to adverse events.
“We anticipate that functional evaluation of older patients will allow us to actively recommend SBRT [an approach less likely than other current treatments to cause adverse events] to older patients who are in relatively good condition but hesitant to receive treatment,” the investigators wrote.
The authors did not receive special funding for the study, and had no conflicts of interest.
SOURCE: Maebayashi T et al. J Geriatr Oncol. 2018 Mar 22. doi: 10.1016/j.jgo.2018.03.005.